Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | -4.59% | -5.45% | +89.09% |
19/04 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
01/04 | Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Evolution of the average Target Price on Xilio Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Xilio Therapeutics, Inc.
Morgan Stanley | |
Chardan Research | |
Raymond James | |
HC Wainwright | |
Cowen | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- XLO Stock
- Consensus Xilio Therapeutics, Inc.